Rituximab?Mycophenolate Versus Mycophenolate in Patients With Interstitial Lung Disease (ILD) Secondary to Systemic Autoimmune Diseases (SAD): A Real-World Experience - Amsterdam 2025

Management of interstitial lung diseases of known causes

Chair(s): GEORGE MARGARITOPOULOS, Leng Cheng Sia

Session type: Poster session

Rituximab?Mycophenolate Versus Mycophenolate in Patients With Interstitial Lung Disease (ILD) Secondary to Systemic Autoimmune Diseases (SAD): A Real-World Experience

Cesar Alejandro Araque Molina

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Radiological patterns and their impact on prognosis in interstitial lung disease with ANCA-Associated vasculitis from a tertiary care UK hospital

Ashnish Sinha

Poster

Abstract

Effectiveness of nintedanib in progressive pulmonary fibrosis (PPF) non IPF: a single-centre, real-life study

Giacomo Guglielmi

Poster

Abstract

Pulmonary implications of Primary Sjögren's syndrome a retrospective cohort anaysis

Marius-alexandru Cote?

Poster

Abstract

Diagnostic evaluation and management of fibrotic hypersensitivity pneumonitis (fHP): Experience from a UK tertiary centre

Trishala Raj

Poster

Abstract

Current Treatment Patterns and factors associated with Therapy Choices in SSc-ILD

Corrado Campochiaro

Poster

Abstract

Real-life cohort study of patients with progressive pulmonary fibrosis receiving antifibrotic therapy

Nanna Makholm Østergård

Poster

Abstract

Acute use of nintedanib for rapidly progressive pulmonary fibrosis: experience of inpatient use at a tertiary interstitial lung disease service

Jessica Clements

Poster

Abstract

Impact of dexamethasone on respiratory sequelae in the follow-up of hospitalized patients with Sars-Cov-2 pneumonia

David Espejo Castellanos

Poster

Abstract

Efficacy of inhaled treprostinil versus PDE5 inhibitors and no treatment in ILD-PH

Laura Price

Poster

Abstract

Minimizing steroid toxicity in interstitial lung diseases

Alberto Casey

Poster

Abstract

Lung auscultation for detecting interstitial lung disease in systemic sclerosis: Retrospective study

Felix Wireko

Abstract

Real-world effectiveness of antifibrotics in slowing FVC and DLCO decline in progressive pulmonary fibrosis

Aycan Yüksel

Poster

Abstract

RituximabMycophenolate Versus Mycophenolate in Patients With Interstitial Lung Disease (ILD) Secondary to Systemic Autoimmune Diseases (SAD): A Real-World Experience

Cesar Alejandro Araque Molina

Poster

Abstract

Retrospective, multicentre (UK) analysis of bleeding risk from nintedanib with or without concomitant anticoagulation in fibrotic ILD patients

Nixon Leung

Poster

Abstract

Prognostic factors differ in patients commencing antifibrotics for idiopathic pulmonary fibrosis versus progressive pulmonary fibrosis.

Gabriella Marina Ruffino

Poster

Abstract

Baseline characteristics of participants in the MYCOHYPE study: the first randomised controlled trial of mycophenolate mofetil in fibrotic HP

Sahajal Dhooria

Poster

Abstract

Clinical characterization of serum SP-D and serum KL-6 levels in patients with drug-induced lung injury associated with lung cancer chemotherapy

Tomoyuki Takahashi

Poster

Abstract

Ruxolitinib add-on to corticosteroids for patients with severe checkpoint inhibitor-related pneumonitis?an interim analysis

Xiaoxing Gao

Abstract

Characteristics and Outcomes of patients treated with CDK4/6 inhibitors who develop interstitial lung disease

Gautam George

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}